GlaxoSmithKline PLC – Consensus Indicates Potential 11.4% Upside

Broker Ratings

GlaxoSmithKline PLC found using ticker (GSK) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 52.5 and 45.94 with a mean TP of 49.81. With the stocks previous close at 44.72 this would imply there is a potential upside of 11.4%. The 50 day moving average now sits at 43.61 while the 200 day moving average is 42.25. The company has a market capitalisation of $114,662m. You can visit the company’s website by visiting: https://www.gsk.com

The potential market cap would be $127,713m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics; Alector; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences and Vir Biotechnology GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

You might also enjoy reading  GSK plc - Consensus Indicates Potential 17.2% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index